A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

NCT03726879 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

454

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Atezolizumab
DRUG: Placebo
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Paclitaxel
DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Trastuzumab Emtansine

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]